IN2014MN02518A - - Google Patents

Info

Publication number
IN2014MN02518A
IN2014MN02518A IN2518MUN2014A IN2014MN02518A IN 2014MN02518 A IN2014MN02518 A IN 2014MN02518A IN 2518MUN2014 A IN2518MUN2014 A IN 2518MUN2014A IN 2014MN02518 A IN2014MN02518 A IN 2014MN02518A
Authority
IN
India
Prior art keywords
host cells
ssi
cho
stable
produce
Prior art date
Application number
Other languages
English (en)
Inventor
James Rance
Robert Young
Michael J Agostino
Mark Moffat
Lin Zhang
Baohong Zhang
Original Assignee
Lonza Biologics Plc
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Biologics Plc, Pfizer filed Critical Lonza Biologics Plc
Publication of IN2014MN02518A publication Critical patent/IN2014MN02518A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN2518MUN2014 2012-06-22 2013-06-20 IN2014MN02518A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261663147P 2012-06-22 2012-06-22
EP12185330.3A EP2711428A1 (fr) 2012-09-21 2012-09-21 Intégration spécifique d'un site
PCT/EP2013/062859 WO2013190032A1 (fr) 2012-06-22 2013-06-20 Site spécifique d'intégration

Publications (1)

Publication Number Publication Date
IN2014MN02518A true IN2014MN02518A (fr) 2015-07-17

Family

ID=46888327

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2518MUN2014 IN2014MN02518A (fr) 2012-06-22 2013-06-20

Country Status (19)

Country Link
US (2) US10280436B2 (fr)
EP (2) EP2711428A1 (fr)
JP (1) JP6053923B2 (fr)
KR (1) KR101761709B1 (fr)
CN (1) CN104379753B (fr)
AU (1) AU2013279333C1 (fr)
BR (1) BR112014032299B1 (fr)
CA (1) CA2876280C (fr)
DK (1) DK2864489T3 (fr)
EA (1) EA034039B1 (fr)
ES (1) ES2629509T3 (fr)
HK (1) HK1202580A1 (fr)
IL (1) IL236347A0 (fr)
IN (1) IN2014MN02518A (fr)
MX (1) MX351727B (fr)
PL (1) PL2864489T3 (fr)
SG (1) SG11201408576QA (fr)
TW (1) TWI523946B (fr)
WO (1) WO2013190032A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
ES2789073T3 (es) 2015-04-27 2020-10-23 Momenta Pharmaceuticals Inc Método de fabricación de una proteína terapéutica
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11028410B2 (en) 2016-01-27 2021-06-08 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
CN109071633B (zh) * 2016-04-20 2022-11-18 瑞泽恩制药公司 基于使用表达增强性基因座来制备抗体的组合物和方法
CN116515757A (zh) * 2016-04-20 2023-08-01 瑞泽恩制药公司 基于使用表达增强性基因座来制备抗体的组合物和方法
CA3053304A1 (fr) 2017-02-17 2018-08-23 Lonza Ltd. Cellules de mammifere pour produire des virus adeno-associes
KR102630357B1 (ko) * 2017-02-17 2024-01-30 론자 리미티드 단백질 발현이 어려운 다중-부위 ssi 세포
GB201703418D0 (en) * 2017-03-03 2017-04-19 Ge Healthcare Bio Sciences Ab Method for cell line development
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
CN107557390A (zh) * 2017-09-18 2018-01-09 江南大学 一种筛选cho细胞系高表达位点的方法
WO2020072480A1 (fr) * 2018-10-01 2020-04-09 Lonza Ltd Cellules ssi à expression transgénique prévisible et stable et procédés de formation
TW202039852A (zh) * 2018-12-21 2020-11-01 美商建南德克公司 核酸之靶向整合
JPWO2020204055A1 (fr) 2019-04-02 2020-10-08
CN114746554A (zh) 2019-11-14 2022-07-12 隆萨有限公司 细胞选择的方法
KR102335242B1 (ko) * 2020-05-22 2021-12-02 인천대학교 산학협력단 Fer1L4 유전자에 부위-특이적 통합된 RMCE 랜딩 패드를 포함하는 CHO 세포
EP4189093A1 (fr) 2020-07-30 2023-06-07 Pfizer Inc. Cellules ayant des duplications de gènes et leurs utilisations
CA3227875A1 (fr) 2021-08-02 2023-02-09 Pfizer Inc. Vecteurs d'expression ameliores et leurs utilisations
WO2023148598A1 (fr) 2022-02-02 2023-08-10 Pfizer Inc. Prototrophie cystéinique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
CA2289277C (fr) 1997-04-24 2013-02-12 University Of Washington Modification genetique ciblee au moyen de vecteurs parvoviraux
EP1771483A1 (fr) * 2004-07-20 2007-04-11 Symphogen A/S Anticorps polyclonal recombine anti-rhesus d et procedes de production
JP4665115B2 (ja) * 2004-08-06 2011-04-06 独立行政法人理化学研究所 骨・関節疾患感受性遺伝子およびその用途
CA2615532C (fr) 2005-07-26 2016-06-28 Sangamo Biosciences, Inc. Integration et expression ciblees de sequences d'acides nucleiques exogenes

Also Published As

Publication number Publication date
AU2013279333B9 (en) 2017-06-29
BR112014032299A2 (pt) 2017-08-01
AU2013279333C1 (en) 2017-08-31
EP2864489A1 (fr) 2015-04-29
BR112014032299B1 (pt) 2021-09-21
DK2864489T3 (en) 2017-07-17
US11326185B2 (en) 2022-05-10
KR101761709B1 (ko) 2017-07-26
HK1202580A1 (en) 2015-10-02
EP2711428A1 (fr) 2014-03-26
AU2013279333A1 (en) 2015-02-12
CA2876280A1 (fr) 2013-12-27
ES2629509T3 (es) 2017-08-10
US20150167020A1 (en) 2015-06-18
TWI523946B (zh) 2016-03-01
EA201590068A1 (ru) 2015-04-30
CN104379753A (zh) 2015-02-25
IL236347A0 (en) 2015-02-26
MX351727B (es) 2017-10-26
TW201420762A (zh) 2014-06-01
CA2876280C (fr) 2018-02-06
EA034039B1 (ru) 2019-12-20
KR20150029693A (ko) 2015-03-18
PL2864489T3 (pl) 2017-09-29
US10280436B2 (en) 2019-05-07
JP6053923B2 (ja) 2016-12-27
US20190119702A1 (en) 2019-04-25
AU2013279333B2 (en) 2017-03-30
CN104379753B (zh) 2020-06-09
EP2864489B1 (fr) 2017-03-29
MX2014015612A (es) 2015-07-14
WO2013190032A1 (fr) 2013-12-27
SG11201408576QA (en) 2015-03-30
JP2015519914A (ja) 2015-07-16

Similar Documents

Publication Publication Date Title
IN2014MN02518A (fr)
ZA202201361B (en) Methods and compositions comprising purified recombinant polypeptides
PH12018501839A1 (en) St2l antagonists and methods of use
CR20140463A (es) Compuestos de heterociclilo como inhibidores de mek
MX2015002873A (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r.
UY34824A (es) Nucleósidos de espirooxetano de uracilo
EP2865656A4 (fr) Procédé de fabrication d'une plaque de verre ayant une partie courbe et plaque de verre ayant une partie courbe
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX2020002544A (es) Sales de glicopirrolato.
ZA201401613B (en) Method for producing highly pure platinum powder, as well as platinum powder that can be obtained according to said method, and use thereof
PH12016500598A1 (en) Protoxin-ii variants and methods of use
IN2013DE00266A (fr)
BR112014027219A2 (pt) método
PL3042880T3 (pl) Sposób wytwarzania płyty szklanej
IN2015DN00085A (fr)
EP2971288A4 (fr) Compositions, procédés et systèmes informatiques associés à la production et l'administration de lymphocytes t modifiés
BR112014029620A2 (pt) unidade de ventilação
EP3022293A4 (fr) Procédés de modélisation du métabolisme de la cellule ovarienne de hamster (cho)
BR112015002145A2 (pt) pino intramedular
MX2019002801A (es) Uso de una composicion farmaceutica que comprende un anticuerpo anti-il-4r en el tratamiento de la dermatitis atopica.
IN2013MU01918A (fr)
GB201321642D0 (en) Technique to enhance the coincidence of focussed, converging, light beams
MX2016001694A (es) Formulacion de vacuna de sacarido.
GT201200007S (es) Dispositivo para iluminacion exterior (no.1)
UA80618U (en) Use of n-steroylethanolamine as radiomodifier